

## SUPPLEMENTARY MATERIAL

### Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies

Stefano Stano,<sup>1</sup> Fabio Cacciapaglia,<sup>1,2</sup> Laura Coladonato,<sup>1</sup>  
Giuseppe Lopalco,<sup>1</sup> Florenzo Iannone,<sup>1</sup> Marco Fornaro<sup>1</sup>

<sup>1</sup>Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari; <sup>2</sup>Department of Medicine and Surgery, LUM 'G. De Gennaro', Casamassima, Italy

**Correspondence:** Marco Fornaro, Unit of Rheumatology, Department of Precision and Regenerative Medicine and Ionian Area, Piazza G Cesare, 11 70124 Bari, Italy.


E-mail [marco.fornaro@uniba.it](mailto:marco.fornaro@uniba.it)

**Key words:** myositis, rituximab, safety, effectiveness.

**Supplementary Table 1. Autoantibody profile of idiopathic inflammatory myopathy patients treated with rituximab.**

Autoantibody profile	IIM patients (n. 41)
anti-SSA (Ro52), n. (%)	14 (34.1)
anti-Jo1, n. (%)	11 (26.8)
anti-HMGCR, n. (%)	5 (12.2)
anti-Mi2, n. (%)	4 (9.7)
anti-MDA5, n. (%)	4 (9.7)
anti-RNP, n. (%)	3 (7.3)
anti-PL12, n. (%)	2 (4.9)
anti-PmScl 75/100, n. (%)	2 (4.9)
anti-TIF1gamma, n. (%)	2 (4.9)
anti-SRP, n. (%)	1 (2.4)
anti-KS, n. (%)	1 (2.4)
anti-Ku, n. (%)	1 (2.4)
anti-NXP2, n. (%)	1 (2.4)
anti-SAE, n. (%)	1 (2.4)
anti-OJ, n. (%)	1 (2.4)

IIM, idiopathic inflammatory myopathy.



**Supplementary Figure 1. Refractory organ involvement at baseline in idiopathic inflammatory myopathy patients with indication to rituximab treatment. DM, dermatomyositis; ASS, anti-synthetase syndrome; PM, polymyositis; IMNM, immune-mediated necrotizing myopathy.**